Columbia University Vagelos College of Physicians and Surgeons

Med Schools Fear Board Exam Changes Could Impede Diversity and MD Preparedness

Retrieved on: 
Wednesday, August 23, 2023
Cognition, Medical school, USMLE, University, Interview, Workplace, Anxiety, Physician, University of California, San Francisco, Duke University School of Medicine, University of California, Kate Campbell, Student, National Resident Matching Program, NRMP, Patient, UCSF, Columbia University Vagelos College of Physicians and Surgeons, School, USMLE Step 1, DEI, UCLA, Mental health, Nursing, Medicine, Surgeon

MOORESVILLE, N.C., Aug. 23, 2023 /PRNewswire-PRWeb/ -- The United States Medical Licensing Examination® (USMLE®) is undeniably one of toughest and most competitive tests on the planet. Developed to assess medical students' preparedness for the workplace, passing the three-step test is required for anyone wishing to practice medicine in the U.S.

Key Points: 
  • Until recently, USMLE Step 1 was based on a three-digit score, from 1 to 300.
  • The higher the score, the more likely a student would match into their desired residency specialty and program.
  • More than half of respondents indicated that 5% or more of their medical students undergo formal remediation or delays each year.
  • Vendors, educators, and policymakers must work together to ensure positive outcomes for all medical students and ultimately the patients they treat."

Otsuka Medical Devices and Recor Medical Announce Positive Vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise™ Ultrasound Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
Wednesday, August 23, 2023
Medical Devices, FDA, Health, Health Technology, Clinical Trials, Cardiology, Columbia University, Blood pressure, CE, Medical device, Physician, RDN, Hypertension, PMA, Patient, Disease, Surgeon, Columbia University Vagelos College of Physicians and Surgeons, Mortality, Hospital, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Medicine

Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) and Recor Medical, Inc. (“Recor”, subsidiary of Otsuka Medical Devices) announced the U.S. Food and Drug Administration (FDA) Circulatory Systems Devices Panel of the Medical Devices Advisory Committee met to discuss the pre-market approval application (PMA) for the Paradise™ Ultrasound Renal Denervation (RDN) system, indicated to reduce blood pressure in patients with hypertension.

Key Points: 
  • Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) and Recor Medical, Inc. (“Recor”, subsidiary of Otsuka Medical Devices) announced the U.S. Food and Drug Administration (FDA) Circulatory Systems Devices Panel of the Medical Devices Advisory Committee met to discuss the pre-market approval application (PMA) for the Paradise™ Ultrasound Renal Denervation (RDN) system, indicated to reduce blood pressure in patients with hypertension.
  • The committee voted 12 to 0 in favor of the Paradise Ultrasound RDN system with regard to safety and 8 to 3 in favor with regard to efficacy, with one vote abstaining.
  • The committee also voted 10 to 2 in favor that the Paradise system benefits outweigh the risks.
  • The Paradise Ultrasound RDN system bears the CE mark for the treatment of hypertension and is an investigational device in the United States and Japan.

Recor Medical and Otsuka Medical Devices Announce Positive Vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise™ Ultrasound Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
Wednesday, August 23, 2023
Biotechnology, FDA, Health, Medical Devices, Columbia University, Blood pressure, CE, Physician, Multimedia, RDN, Hypertension, PMA, Patient, Surgeon, Disease, Columbia University Vagelos College of Physicians and Surgeons, Mortality, Hospital, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Medicine

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) announce the U.S. Food and Drug Administration (FDA) Circulatory Systems Devices Panel of the Medical Devices Advisory Committee met to discuss the pre-market approval application (PMA) for the Paradise™ Ultrasound Renal Denervation (RDN) system, indicated to reduce blood pressure in patients with hypertension.

Key Points: 
  • Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) announce the U.S. Food and Drug Administration (FDA) Circulatory Systems Devices Panel of the Medical Devices Advisory Committee met to discuss the pre-market approval application (PMA) for the Paradise™ Ultrasound Renal Denervation (RDN) system, indicated to reduce blood pressure in patients with hypertension.
  • The overall vote from the committee was favorable that there was sufficient data to support the use of the device in patients with uncontrolled hypertension.
  • The committee also voted 10 to 2 in favor that the Paradise system benefits outweigh the risks.
  • The Paradise Ultrasound RDN system bears the CE mark for the treatment of hypertension and is an investigational device in the United States and Japan.

TFC Therapeutics Launches to Advance Novel Platform and Technologies in Cancer Biology

Retrieved on: 
Thursday, August 17, 2023
Columbia University, Metastasis, Pfizer, Physician, Cancer, Hope, Innovation, ARCH Venture Partners, MBA, Cell, TFC, TMH, Advisory board, Doctor of Philosophy, Assistant, ARCH, Global Health, Patient, Edward, Columbia University Vagelos College of Physicians and Surgeons, Drug discovery, Bill, Therapy, Recurrence, Alexandria Real Estate Equities, Pharmaceutical industry, Pomona College, Economics, Surgeon, Medicine

NEW YORK, Aug. 17, 2023 /PRNewswire/ -- TFC Therapeutics (TFC), a biotechnology company focused on developing novel biologics to target and eliminate key drivers of cancer recurrence and metastasis, today announced a financing led by ARCH Venture Partners with participation from Breakout Ventures, Alexandria Real Estate Equities, and Alumni Ventures.  In connection with the financing, Steven Gillis, Ph.D., Managing Director at ARCH, has been appointed as Chairman of the TFC Board of Directors. 

Key Points: 
  • In connection with the financing, Steven Gillis, Ph.D., Managing Director at ARCH, has been appointed as Chairman of the TFC Board of Directors.
  • TFC has entered into an exclusive license agreement with Columbia University to develop a drug discovery platform that targets Tumor Macrophage Hybrid (TMH) cells.
  • TFC's emerging platform technologies are focused on the elimination of TMH cells, which are found in the bloodstream of patients with cancer.
  • "At TFC, we remain committed to bringing forward a new approach to treatment of cancer metastasis and relapse that will benefit patients living with cancer," said Jennifer Power, Chief Executive Officer of TFC Therapeutics.

Stanford University Student Shares Educational and Career Updates After Receiving SBB Research Group Foundation STEM Scholarship

Retrieved on: 
Saturday, August 12, 2023
Columbia University, Learning, Brain, Stanford University, Columbia University Vagelos College of Physicians and Surgeons, Science, technology, engineering, and mathematics, Columbia University College of Dental Medicine, Research, Gene expression, Cerebrospinal fluid, Student, Patient, Surgeon, STEM, Biology, Breast cancer, Nursing, Science, Mathematics, Engineering, Physician, Human biology

CHICAGO, Aug. 11, 2023 /PRNewswire-PRWeb/ -- The SBB Research Group Foundation is proud to highlight the continued success of Bryanna Godfrey after receiving the STEM Scholarship in 2021. The $2,500 award empowers students to create value for society by pursuing higher learning through interdisciplinary combinations of Science, Technology, Engineering, and Mathematics (STEM).

Key Points: 
  • CHICAGO, Aug. 11, 2023 /PRNewswire-PRWeb/ -- The SBB Research Group Foundation is proud to highlight the continued success of Bryanna Godfrey after receiving the STEM Scholarship in 2021.
  • The $2,500 award empowers students to create value for society by pursuing higher learning through interdisciplinary combinations of Science, Technology, Engineering, and Mathematics (STEM).
  • Godfrey received the SBB Research Group Foundation STEM Scholarship during her senior year at Stanford University while pursuing a degree in Human Biology.
  • The SBB Research Group Foundation is honored to have played a role in Godfrey's success.

Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

Retrieved on: 
Monday, August 7, 2023
Takeda Pharmaceutical Company, Business development, Partnership, Novartis Institute for Tropical Diseases, University, Gastroenterology, Doctor of Philosophy, Takeda, Head, Physician, Roche, University of California, Research, Biomedical Research, Strategic planning, Rutgers University, Gastrointestinal tract, Novartis, Patient, Columbia University Vagelos College of Physicians and Surgeons, CBO, M.A, Therapy, Neurology, Pharmaceutical industry, Neuroscience, Voyager, Ophthalmology, Surgeon

CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer (CBO).

Key Points: 
  • CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer (CBO).
  • Shafer is a seasoned healthcare executive with more than 15 years of experience in corporate and business development at prominent biopharmaceutical companies, as well as deep knowledge in neurology.
  • She previously held multiple corporate and business development roles of increasing responsibility during her tenures at Takeda, Novartis and Roche.
  • “I look forward to helping the team leverage business development and strategy to achieve its mission of advancing life-changing genetic medicines for neurological diseases.”

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

Retrieved on: 
Thursday, July 27, 2023
Chugai Pharmaceutical Co., Physician, COVID-19, New York University Grossman School of Medicine, Immune tolerance, Drug, Licensure, Hope, Immunotherapy, Hypercholesterolemia, Columbia University Vagelos College of Physicians and Surgeons, Novartis, Laboratory, Surgeon, PCSK9, Mount Sinai Medical Center, Knowledge, Ulo, Columbia University College of Dental Medicine, Regeneron Pharmaceuticals, Health, Management, Pharmaceutical industry, Sunovion

CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity’s leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023. He will remain as a member of Vaxxinity’s board of directors.

Key Points: 
  • CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity’s leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023.
  • Peter will oversee the overall scientific direction of Vaxxinity’s platform and programs, and lead the development efforts at Vaxxinity.
  • “Get ready for the next wave of innovative drug science at Vaxxinity,” said Mei Mei Hu, CEO of Vaxxinity.
  • We look forward to continuing to work with Ulo and to benefit from his expertise in his role as an advisor to Vaxxinity.”

First U.S. Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study

Retrieved on: 
Tuesday, July 11, 2023
General Health, Health, Cardiology, Medical Devices, Heart failure, Richard M. Ross Heart Hospital, Physician, Heart, Principal investigator, MD, Patient, Division, Columbia University Vagelos College of Physicians and Surgeons, Surgeon, Weill Cornell Medicine, University College London Hospitals NHS Foundation Trust, Joe Byrd (Cherokee Nation Principal Chief), Medical device, Medicine

FIRE1 today announced that the first U.S. patients have been successfully implanted with its FIRE1™ System for remote heart failure monitoring in an Early Feasibility Study.

Key Points: 
  • FIRE1 today announced that the first U.S. patients have been successfully implanted with its FIRE1™ System for remote heart failure monitoring in an Early Feasibility Study.
  • The study will assess FIRE1’s novel solution to improve outcomes for heart failure patients.
  • The first patient was implanted at Austin Heart, Texas, where Kunjan Bhatt, MD, leads the study as Principal Investigator and Thomas McMinn, MD, performed the implants.
  • “We are delighted to announce the first implants in the U.S. of this new, transformative technology for patients with chronic heart failure,” said Dr. Bhatt.

The Knot Worldwide Welcomes Marketing and Consumer Technology Leader Carolyn Everson to its Board of Directors

Retrieved on: 
Monday, June 26, 2023
Bridal, Retail, The Coca-Cola Company, Advertising, Viacom, Columbia University Vagelos College of Physicians and Surgeons, Gen, Meta, Permira, Policy, Jefferson Literary and Debating Society, Everson, Microsoft, The Knot Worldwide, Council, Generation Z, Villanova University, Name, M.B.A, Foreign policy, Harvard Business School, Senior advisor, Humane society, Knot, Family, The Walt Disney Company, Management, Instacart

The Knot Worldwide , a leading global marketplace and family of brands championing celebration, announced today that Carolyn Everson has joined the organization’s board of directors , effective March 22, 2023.

Key Points: 
  • The Knot Worldwide , a leading global marketplace and family of brands championing celebration, announced today that Carolyn Everson has joined the organization’s board of directors , effective March 22, 2023.
  • Everson brings over 28 years of experience to The Knot Worldwide’s board, including having held executive and advisory roles at global consumer businesses.
  • Most recently, Everson served as President of Instacart, where she oversaw the fast-growing company’s advertising, partnerships, policy and legal teams.
  • “I’m incredibly excited to be a part of The Knot Worldwide’s board during a time when the wedding industry is reaching an inflection point,” said Carolyn Everson.

NewYork-Presbyterian Announces $25 Million Gift from the W. P. Carey Foundation to Transform Residency Program

Retrieved on: 
Thursday, June 22, 2023
Telehealth, Partnership, Data wrangling, PAP, Physician, Curriculum, COVID-19, Stroke, Medicine, Research, Hospital, Weill Cornell Medicine, Patient, Columbia University Vagelos College of Physicians and Surgeons, Machine learning, Surgeon, TAVR, Greater New York, Artificial intelligence, AI, Pharmaceutical industry, Nursing, New Yorker, NewYork-Presbyterian Hospital

NEW YORK, June 22, 2023 /PRNewswire/ -- NewYork-Presbyterian today announced a $25 million gift from the W. P. Carey Foundation to prepare the next generation of physician leaders to shape the future of medicine.

Key Points: 
  • NEW YORK, June 22, 2023 /PRNewswire/ -- NewYork-Presbyterian today announced a $25 million gift from the W. P. Carey Foundation to prepare the next generation of physician leaders to shape the future of medicine.
  • "We are grateful to the W. P. Carey Foundation for their steadfast partnership and commitment to developing the future leaders of medicine," said Dr. Steven J. Corwin, president and CEO of NewYork-Presbyterian.
  • The NewYork-Presbyterian enterprise-wide graduate medical education program has been named the W. P. Carey Residency Program.
  • "We look forward to seeing the positive impact the W. P. Carey Residency Program will have on the future of medicine."